SAN ANTONIO BREAST CANCER SYMPOSIUM
December 6-10, 2022
Seven important Presentations from the SABCS 2022 Press Briefings
- T-DXd Yields Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously Treated with T-DM1
- T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2-positive Metastatic Breast Cancer
- Neoadjuvant Trastuzumab Deruxtecan Shows Clinical Activity in Patients With HER2-low Breast Cancer
- Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor-positive, HER2-negative Breast Cancer
- Adding Capivasertib to Fulvestrant Improves Progression-free Survival in Patients With Advanced Hormone Receptor-positive Breast Cancer
- Treatment Decision Guided by Circulating Tumor Cell Count May Improve Long-term Outcomes for Patients with Metastatic Breast Cancer
- Breast Cancer Patients Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-term Recurrence Rates
Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine:
Primary results of the randomized, phase 3 study DESTINY-Breast02
Recorded @ SABCS 2022, December 7
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Recorded @ SABCS 2022, December 7
TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
Recorded @ SABCS 2022, December 7
Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer:
Results of the randomized, multi-dose Phase 2 SERENA-2 trial
Recorded @ SABCS 2022, December 8
Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor- positive/human epidermal growth factor receptor 2-negative advanced breast cancer:
Results from the Phase III CAPItello-291 trial
Recorded @ SABCS 2022, December 8
Circulating Tumor Cells-driven choice of first line therapy for ER+ HER2- metastatic breast cancer: overall survival analysis of the randomized STIC CTC trial
Recorded @ SABCS 2022, December 8
Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13)
Recorded @ SABCS 2022, December 8